[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560521":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":24,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":24,"enrollmentInfo":59,"targetDuration":24,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Region Skane","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Start standard dose adenosine followed by high dose adenosine","ACTIVE_COMPARATOR","Subjects randomized to this arm will undergo the first stress perfusion acquisition with a dose of 140 μg\u002Fkg\u002Fmin adenosine, followed by a second stress perfusion acquisition with the dose of 210 μg\u002Fkg\u002Fmin adenosine.",[13],"Drug: Adenosine",{"label":15,"type":10,"description":16,"interventionNames":17},"Start high dose adenosine followed by standard dose adenosine","Subjects randomized to this arm will undergo the first stress perfusion acquisition with a dose of 210 μg\u002Fkg\u002Fmin adenosine, followed by a second stress perfusion acquisition with the dose of 140 μg\u002Fkg\u002Fmin adenosine.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Adenosine","Standard dose 140 μg\u002Fkg\u002Fmin and high dose 210 μg\u002Fkg\u002Fmin adenosine",[15,9],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Henrik Engblom, MD, PhD","CONTACT","046171000","henrik.engblom@med.lu.se",[32],{"facility":33,"status":34,"city":35,"state":24,"zip":24,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital","RECRUITING","Lund","Sweden","SE",{"type":39,"coordinates":40},"Point",[41,42],13.19321,55.70584,{"lat":42,"lon":41},[45],{"name":46,"role":28,"phone":29,"phoneExt":24,"email":24},"Henrik Engblom, Professor, MD",{"type":48,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100560521","phase-4-hyperemic-myocardial-perfusion-by-adenosine-at-different-doses-100560521",false,"NCT06578234","Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses","HYPER","Inclusion Criteria:\n\nPatients:\n\n1. The subject has given their written consent to participate in the trial.\n2. Are referred to Department of Clinical Physiology, Skåne University Hospital, for suspected or known CCS or heart failure\n3. Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \\>80 years old)\n4. Matches the inclusion criteria for no known heart failure (group b) or known heart failure (group c)\n5. No caffein intake \\\u003C24h prior to the examination\n\nHealthy volunteers:\n\n1. The subject has given their written consent to participate in the trial.\n2. Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \\>80 years old)\n3. No caffein intake \\\u003C24h prior to the examination\n\nExclusion Criteria:\n\nPatients:\n\n1. Acute referral (in-house patients)\n2. Clinically unstable\n3. Acute chest pain\n4. Severe or decompensated heart failure\n5. Non sinus rhythm (e.g. atrial fibrillation)\n6. Asthma or severe chronic obstructive pulmonary disease\n7. Known chronic renal failure (eGFR \\\u003C45mL\u002Fmin\u002F1.73m2)\n8. AV-block II or III\n9. Left Bundle Branch Block\n10. Systolic blood pressure \\\u003C90 mmHg or \\>230 mmHg at rest\n11. Increased intracranial pressure\n12. Known allergy or adverse reaction to adenosine or mannitol\n13. Known allergy or adverse reaction to gadolinium contrast agents\n14. Treatment with medication containing dipyradimol or teofyllamin\u002Fteofyllin\n15. Claustrophobia\n16. Devices contraindicated to CMR imaging (pacemaker, implants, intracranial clips etc)\n17. Pregnancy or breast feeding (screened by question only)\n18. Inability to give informed consent due to mental state, language difficulties etc\n\nHealthy volunteers:\n\n1. Any of the exclusion criteria for patients\n2. Blood pressure \\> 140\u002F90 measured according to clinical routine\n3. Known systemic disease\n4. Known cardiac disease\n5. Cardiovascular medication\n6. Medication that might influence cardiovascular health\n7. Smoking",true,"ALL","40 Years",{"count":60,"type":61},180,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","Adenosine is a commonly used pharmaceutical stressor at cardiac magnetic resonance examinations to assess suspected chronic coronary syndrome (CCS). However, several studies have reported that the current use of adenosine does not induce adequate hyperemic response in a substantial number of patients, leading to false diagnostics. The aim of this trial is to investigate the hyperemic effect of the standard dose of adenosine (140 microgram\u002Fkg\u002Fmin) to the high dose of adenosine (210 microgram\u002Fkg\u002Fmin) to improve the diagnostic methods using adenosine as a stressor and ultimately improve treatment decisions and patient prognosis in CCS.",[67,68,69],"Chronic Coronary Syndrome","Coronary Artery Disease","Ischemic Heart Disease",[71,72,21],"Myocardial perfusion","Cardiac Magnetic Resonance","2025-06-26",{"date":75,"type":76},"2025-06-27","ACTUAL",{"date":78,"type":76},"2024-10-23",{"date":80,"type":61},"2026-12-31",{"name":5,"class":6},1]